Teva Innovative Medicine & Biosimilar Pipeline

Pipeline is current as of July 2026

Download PDF

  • Novel Biologics
  • Small Molecules
  • Biosimilars

Approved

Biosimilar to Prolia®

(denosumab)

Launched regional in Europe and approved in US

Under Regulatory Review

Biosimilar to Simponi®

(golimumab)

In collaboration with Alvotech for the U.S. market.

Biosimilar to Simponi Aria®

(golimumab)

In collaboration with Alvotech for the U.S. market.

Biosimilar to Eylea®

(aflibercept)

In collaboration with Alvotech for the U.S. market.

Olanzapine LAI (TEV-'749)

  • Schizophrenia

Submitted to FDA December 2025, submitted to EMA April 2026

Ecopipam (EBS-101)

  • Tourette's Syndrome

Submitted to FDA June 2026

Biosimilar to Xolair®

(omalizumab)

Biosimilar to Xgeva®

(denosumab)

Launched regional in Europe and under regulatory review in US

Biosimilar to Entyvio®

(vedolizumab)

In collaboration with Alvotech for the U.S. market.

Clinical

Biosimilar to Entyvio® SC

(vedolizumab)

In collaboration with Alvotech for the U.S. market.

TEV-‘333

In collaboration with mAbxience.

TEV-'316

In collaboration with mAbxience.

TEV-'292

In collaboration with Alvotech for the U.S. market.

Phase 3

More information

Phase 3 clinical trials are larger trials typically conducted with up to several thousand participants and are designed to establish if the intervention is safe and effective in preparation for product approval. The results show whether or not the intervention is beneficial to a particular group of participants.

Dual Action Rescue Inhaler (DARI) ICS/SABA (TEV-'248)

  • Asthma

In collaboration with Launch Therapeutics.

Duvakitug (TEV-'574)

  • Ulcerative Colitis, Crohn’s Disease

In collaboration with Sanofi.

Phase 2

More information

Phase 2 clinical trials are conducted with up to several hundred participants. They are designed to collect additional information about whether the intervention is safe and effective. The results of these types of clinical trials may be used to design future trials or to develop additional research methods.

Anti-IL-15 (TEV-‘408)

  • Celiac

Emrusolmin (TEV- '286)

  • Multiple System Atrophy

In collaboration with MODAG.

Phase 1

More information

Phase 1 clinical trials are small-scale clinical trials with very few participants to examine the way the intervention (e.g., medication) interacts with the human body. The purpose of the study is to collect information about the safety of the interventions assessed. These trials are typically conducted in healthy participants without a specific medical condition.

Anti-IL-15 (TEV-‘408)

  • Vitiligo

TEV-'192

  • Immunology & Neuroscience

Anti-PD1-IL2 (TEV-’278)

  • Attenukine Oncology

Sery433 (TEV-'287)

  • Neuroscience

In collaboration with MODAG.

Pre-clinical

More information

More information about this phase in drug development.

TEV-'279

  • Neuroscience

TEV-'288

  • Neuroscience

TEV-'285

TEV-'289

TEV-'295

In collaboration with Alvotech for the U.S. market.

TEV-'296

In collaboration with Alvotech for the U.S. market.

Bx Ocrevus Zunovo

In collaboration with Polpharma

Bx Ocrevus

In collaboration with Polpharma

TEV-’325

  • Immunology

No drugs found for your filtering criteria

Your filtering criteria did not match any drugs we currently have in the pipeline. Reset filters to see all drugs or modify your filtering criteria.

Reset Filters

Teva innovative medicine and biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of July 2026